Articles

R. Donald Harvey believes that developing well-tolerated drugs is the key to improving the standard of care in managing patients with hematologic malignancies. Read More ›

Addition of Obinutuzumab or Rituximab to Chlorambucil in Treatment-Naive Patients with CLL: Updated Survival Analysis from the CLL11 Study

ASH 2015 – Castleman's Disease, Lymphoma & CLL

The Role of Patient Support Services

ASH 2015 – Multiple Myeloma

R. Donald Harvey stresses the importance of patient support services in addressing financial challenges and building support communities for both patients and their families. Read More ›

Impact of High-Risk Prognostic Parameters on Ibrutinib/Bendamustine/Rituximab versus Bendamustine/Rituximab Treatment Outcomes in Patients with Relapsed CLL/SLL: Results from the HELIOS Trial

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Managing Patients on Oral Oncolytics

ASH 2015 – Multiple Myeloma

Ali McBride provides an overview of the role of the pharmacist and the importance of working with a broad team of healthcare providers in managing patients on oral oncolytics. Read More ›

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Exciting Time for Treating Myeloma

ASH 2015 – Multiple Myeloma

R. Donald Harvey speaks about the addition of new medicines and how they can be included in the existing treatment armamentarium. Read More ›

Management of Adverse Events in the HELIOS Trial in Patients with Previously Treated CLL/SLL

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Articles

Page 130 of 147